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Abstract
Background: Acute Multifocal Hemorrhagic Retinal Vasculitis (AMHRV) is a rare disease with unknown incidence
that presents with abrupt onset of visual loss associated with retinal vasculitis, retinal hemorrhage, non-confluent
posterior retinal infiltrates, vitreous cellular inflammation and papillitis in, otherwise, healthy adult individuals.
The reported treatment options for Acute Multifocal Hemorrhagic Retinal Vasculitis are oral corticosteroids, intravitreal
ganciclovir and laser photocoagulation or vitrectomy. We report a child with Acute Multifocal Hemorrhagic Retinal
Vasculitis who was treated with aggressive immunosuppressive therapy resulting in a favorable visual outcome.
Case presentation: A retrospective case report of a 10-year-old African American girl who developed unilateral Acute
Multifocal Hemorrhagic Retinal Vasculitis, which later on progressed bilaterally. We conducted a review of the clinical,
laboratory and photographic records to evaluate her functional and anatomic outcome after aggressive
immunosuppressive treatment. During the first 4 months of treatment of OD with intravitreal ganciclovir,
intravitreal dexamethasone and systemic prednisone, the change in vision in OD improved from light perception (LP)
to counting fingers (CF). During the next 18 months of aggressive systemic treatment of OD and the newly affected
left eye (OS), the change in vision improved from CF in OD and CF in OS to 20/200 in OD and 20/80 in OS.
Management during the 18-month interval included rituximab infusions, cyclophosphamide/methylprednisolone
infusions, prednisone and mycophenolate.
Conclusions: This is the first reported case of Acute Multifocal Hemorrhagic Retinal Vasculitis occurring in a
child. Ophthalmologists should be aware of the need to treat severe Acute Multifocal Hemorrhagic Retinal
Vasculitis with aggressive immunosuppressive agents in collaboration with rheumatologists to obtain the best
possible visual outcome.
Keywords: Acute multifocal hemorrhagic retinal vasculitis, Corticosteroids, Cyclophosphamide, Mycophenolate,
Rituximab, Case report
Background
Acute Multifocal Hemorrhagic Retinal Vasculitis (AMHRV)
is a rare disease with unknown incidence. It was first re-
ported by Blumenkranz et al. in 1988 as an episodic disease
that presents with abrupt onset of visual loss associated
with retinal vasculitis, retinal hemorrhage, non-confluent
posterior retinal infiltrates, vitreous cellular inflammation
and papillitis in, otherwise, healthy adult individuals [1].
Although, the exact etiology of this disease is not known,
many of the features of AMHRV may resemble those of an
acute viral infection and some autoimmune diseases
especially Behcet’s disease [1]. Consequently, it is often
treated, initially, with anti-viral medications without any
improvement. Other conditions with similar ocular findings
can mimic AMHRV including Behcet’s disease, Eales dis-
ease, systemic lupus erythematosus, ocular syphilis, viral
disease and sarcoidosis.
Once the diagnosis of AMHRV is clinically established,
treatment should begin immediately to avoid complica-
tions including epiretinal membranes, retinal neovascular-
ization, iris neovascularization, vitreous hemorrhage, optic
neuropathy or neovascular glaucoma [1, 2] resulting in
visual loss. Currently, treatment options for AMHRV have
included laser photocoagulation, oral corticosteroids, vi-
trectomy and intravitreal ganciclovir [1–3].
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To date, only adults have been described in the litera-
ture to develop AMHRV. Herein, we report a child who
developed AMHRV in her right eye (OD) followed by
left eye (OS) involvement 4 months later, treated with
aggressive immunosuppressive therapy that included the
use of rituximab, cyclophosphamide, methylpredniso-
lone, prednisone and mycophenolate, which resulted in
remarkable improvement in visual acuity. We believe pa-
tients with severe cases of AMHRV may benefit from
early and aggressive immunosuppressive therapy.
Case presentation
A 10-year-old African-American girl with a history of
asthma and eczema had 20/20 vision in both eyes until
August 8, 2011, when she first noticed floaters in her
OD. On August 10, 2011, the patient developed abrupt
onset of visual loss in the OD. She presented to the
emergency department (ED), complaining of unilateral
visual loss in the OD. No other systemic complaints
were reported. Patient was found to have visual acuity of
light perception (LP) in the OD and 20/20 in the OS.
Results of a slit-lamp examination of the OD showed
clear cornea, trace conjunctival injection and a few cells
in the anterior chamber. On fundoscopic exam of the
OD, patient was found to have 1+ cells in the anterior
vitreous as well as severe intraretinal hemorrhage, exu-
dates, perivasculitis and posterior vitritis. The optic
nerve could not be visualized (Fig. 1). Examination of
the OS did not reveal any abnormalities. Intraocular
pressures in both eyes were within normal limits.
Chest x-ray and MRI of the brain did not reveal any
abnormalities. Laboratory examination included complete
blood count, complete metabolic profile, urinalysis, FTA-
abs, human immunodeficiency virus (HIV) panel, and ser-
ology for varicella zoster virus (VZV), herpes simplex
virus (HSV) I/II and toxoplasmosis. Anterior chamber tap
was also done to test the fluid for VZV, HSV I/II and cyto-
megalovirus DNA through polymerase chain reaction
(PCR). We also tested the patient for ANCA associated
vasculitides, rheumatoid arthritis factor (RF), ANA panel,
erythrocyte sedimentation rate (ESR) and angiotensin con-
verting enzyme levels to evaluate for a non-infectious
cause. All of the tests were unremarkable except for:
elevated ESR at 32 mm/h (normal: <20), elevated ACE
levels at 124 U/L (normal: 6–89) and elevated eosino-
phils at 8.5 % (normal: 1–5 %). Fluorescein angiography
(FA) revealed vasculitic process with intraretinal
hemorrhage blocking defects and there was retinal is-
chemic changes (Fig. 2).
Patient was placed on long-term therapy with famcy-
clovir 500 mg for a presumed viral infection. We gave
one mg gancyclovir three times 5 days apart each with
400 microgram dexamethasone intravitreal injections in
OD starting on August 15, 2011. In addition to the in-
jections, patient was started on oral Prednisone 50 mg
daily. Over the next few weeks, retinal vasculitis contin-
ued to improve OD but her visual acuity remained poor
at counting fingers (CF). Fundoscopic exam of the OD
on December 1, 2011, revealed some optic nerve pallor
with ischemic and narrowed vessels with resolution of
retinal hemorrhage (Fig. 3).
Fig. 1 Color photograph of right eye showing severe intraretinal
hemorrhages
Fig. 2 Fluorescein angiography of the right eye showing severe
blocking defects from intraretinal hemorrhage and retinal vasculitis
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While the OD continued to stabilize, the AMHRV
progressed to involve the OS. Patient reported decreased
visual acuity in the OS starting November 29, 2011. Her
visual acuity continued to deteriorate over the next few
days and at the time of exam on December 1, 2011; pa-
tient’s visual acuity was CF. On fundoscopic exam, she
was found to have severe intraretinal hemorrhage with
retinal vein sheathing and whitening (Fig. 4). Rheumatol-
ogy was consulted. Per rheumatology recommendations,
patient was admitted to the hospital for further evaluation
and aggressive treatment. Patient underwent the prior
mentioned laboratory evaluation again. In addition to the
previous laboratory tests, we obtained serum lysozyme
levels, IgG/IgM levels, CH50 levels and A-1-C enzyme
levels. The work-up was unremarkable except for elevated
eosinophils at 8.8 % (normal: 1–5 %), elevated sedimenta-
tion rate of 70 mm/h (normal: 0–20 mm/h) and low
CH50 of 27 U/mL (normal: 31U/mL-60U/mL). On this
occasion, her ACE levels were within normal limits.
Due to her poor vision of CF OD and new onset
AMHRV OS with CF vision, she was aggressively
treated with three infusions of rituximab (650 mg/m2),
two of which were in December 2011 and the third in
June 2012. She also received alternating six cycles of
cyclophosphamide (1 g/m2)/methylprednisolone 500 mg
(1 g/m2) intravenous infusions every 4 weeks from
December 2011-June 2012. In addition to the infusions,
patient was placed on Prednisone 60 mg a day that was
slowly tapered over 7 months. B-cell depletion was moni-
tored through flow cytometry. After the completion of the
infusions and steroid taper, patient was placed on myco-
phenolate 1000 mg BID to prevent recurrence of retinal
vasculitis. Patient’s visual acuity in the OS improved from
CF to 20/80 within 1 month of initiation of aggressive
immunosuppressive treatment and has remained stable.
On the most recent fundoscopic exam of the OS in
June 2013, the optic nerve appeared healthy without
any evidence of vasculitis, hemorrhage or phlebitis
(Fig. 5). Although there was no ischemic changes at the
onset of the disease, retinal ischemia developed later in
FA during follow up. Functional improvement was also
noted in the OD during the aggressive immunosuppres-
sive course of therapy, resulting in visual improvement
from CF to 20/200.
Fig. 3 Color photograph of right eye following resolution of AMHRV
showing optic nerve pallor and narrowed retinal vessels
Fig. 4 Color photograph of left eye showing severe intraretinal
hemorrhage and vasculitis Fig. 5 Color photograph of left eye following resolution of AMHRV
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Discussion
We report a case of AMHRV in a 10-year-old girl who
presented with abrupt onset of visual loss secondary to
severe retinal hemorrhage and vasculitis. On fundo-
scopic exam, we noticed retinal arteritis and phlebitis
with sheathing. Her medical history was unremarkable
except for a prior diagnosis of asthma and eczema. The
disease process in our patient was subsequently bilateral,
with the OS developing the disease 4 months after the
OD. Thorough systemic medical evaluation to determine
the etiology of the retinal vasculitis was unremarkable ex-
cept for elevated ESR and eosinophils. Consequently, the
diagnosis of AMHRV was made on clinical examination.
AMHRV diagnosis is established mainly clinically,
Table 1 summarizes the diagnostic criteria of AMHRV
based on Blumenkranz. Although It is a clear according
to the literature that there is a relation between auto-
immune diseases such as bronchial asthma and AMHRV
which was noticed in Blumenkrank cases and our case
as well, the exact pathophysiology of acute multifocal
hemorrhagic retinal vasculitis is still unknown [1]. It is
probably an unknown viral etiology. Later on, the most
common ocular complications of AMHRV arise from
the retinal ischemic changes. These complications in-
cludes: epidural membrane formation, neovascular glau-
coma, retinal detachment and vitreous hemorrhage [1].
Nothing of the aforementioned problems were noticed
in our patient, since it was newly diagnosed and treated.
A systemic inflammatory disease like Behcet’s disease
may present with similar fundus manifestations and clin-
ical course as our patient. Behcet’s disease is common in
regions along the Silk Road, from the countries of the
Mediterranean to the Far East. It commonly affects
males who are 20–40 years old; however, 26 % of indi-
viduals with Behcet’s disease are younger than 16 years
of age [4]. Based on the new International Criteria for
Behçet’s Disease, a patient scoring ≥ 4 points is classified
as having Behcet’s disease. Ocular lesions, oral aphthosis
and genital aphthosis are each assigned 2 points, while
skin lesions, central nervous system involvement and
vascular manifestations, 1 point each. The pathergy test,
when used, was assigned 1 point. [5]. Our patient does
not fit the aforementioned criteria for Behcet’s disease.
Eales disease presents with fundoscopic findings that
are similar to those found in AMHRV. Eales disease is
an idiopathic inflammatory disease, typically affecting
young men, that is characterized by retinal phlebitis, per-
ipheral non-perfusion and retinal neovascularization [6].
Patients often present with recurrent vitreous hemor-
rhages secondary to retinal neovascularization. Our pa-
tient does not fit the typical patient demographic for Eales
disease and at no point did she develop vitreous hemor-
rhages during her 22-month follow-up. In addition, Eales
disease does not usually present with 360° of retinal
hemorrhage, as was the case with our patient.
Viral retinopathies secondary to herpes class viruses
can mimic the fundoscopic findings of AMHRV. The
presentation can vary from acute retinal necrosis (ARN)
in immunocompetent patient to progressive outer retinal
necrosis (PORN) in an immunocompromised individual
[7]. Vasculitis caused due to a viral infection typically in-
volves the arterioles [7], whereas AMHRV involves the
retinal venules. In addition, PCR was performed on the
anterior chamber fluid and on the vitreous sample ob-
tained from our patient, which showed no evidence of a
herpetic viral process.
Due to the rare presentation of AMHRV, there have
been no controlled trials conducted to determine a de-
finitive treatment protocol for this disease. A thorough
review of the literature yields nine published cases of
AMHRV and the treatments that were utilized. All pa-
tients were adults at the time of presentation, while this
report is the only known case of AMHRV developing in
a child. Blumenkranz et al. reported a series of seven pa-
tients who were treated using oral corticosteroids, aza-
thioprine, panretinal photocoagulation, acyclovir and
anticoagulants [1]. In a case report from Brazil, Amaro
et al. reported improved visual outcome over the long-
term using panretinal photocoagulation and oral cortico-
steroids [2]. Bronner et al. reported using intravitreal
ganciclovir, oral corticosteroids, panretinal photocoagu-
lation and vitrectomy to treat their patient with AMHRV
[3]. Our management, during the treatment of the OD,
included intravitreal ganciclovir, intravitreal dexametha-
sone, famcyclovir and prednisone. Although the treatment
was initiated within a week of symptom onset, it did not
result in a significant improvement in visual acuity. It was,
however, beneficial in improving retinal hemorrhage and
vasculitis. Our decision to use famcyclovir instead of
acyclovir was based on published studies that illustrated
the efficacy of this drug in treating acute retinal necrosis
[8]. Our treatment regimen was significantly altered when
the patient developed AMHRV involving the OS. After
rheumatology consultation, we aggressively treated with
potent immunosuppressants considering her poor vis-
ual prognosis. Patient was treated with rituximab infu-
sions, cyclophosphamide/methylprednisolone infusions,
oral prednisone and mycophenolate. Our decision to
use rituximab and mycophenolate was based on
Table 1 Clinical criteria for diagnosis of AMHRV
Abrupt onset of unilateral or bilateral visual loss
Predominant venular retinal vaculitis
Variable retinal hemorrhages
Nonconfluent posterior retinal infiltrates
Vitreous cellular inflammation
Papillitis
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published studies that illustrated the efficacy of these
drugs in treating retinal vasculitis. Davatchi et al. and
Donnithorne et al. have reported using rituximab infu-
sions for the treatment of refractory retinal vasculitis
secondary to Behcet’s disease and SLE, respectively [9,
10]. In a retrospective cohort study with 257 patients,
Galor et al. found that mycophenolate relieved inflam-
mation significantly faster than methotrexate, while
causing fewer adverse events than azathioprine [11].
We, in conjunction with rheumatology, carefully moni-
tored the patient for the development of side effects. Pa-
tient did develop mild neutropenia during the course of
her treatment, but remained asymptomatic throughout
the 22-month follow-up. Only one month after the
initiation of treatment, which included two cycles of ri-
tuximab infusions, one cycle of cyclophosphamide/
methylprednisolone infusion and oral prednisone; we
noted a remarkable improvement in patient’s visual
acuity in the OS. It improved from CF to 20/80 over a
1 month period and this improvement was sustained
throughout the 22-month follow-up. The OD, only after
initiation of aggressive immunosuppressive therapy, slowly
regained vision from CF to 20/200. Donnithorne et al. re-
ported a similar experience in treating two pediatric cases
with SLE induced retinal vasculitis, where delay in treat-
ment resulted in limited visual recovery [10].
Conclusions
We present the first case of AMHRV developing in a
child. Early treatment with potent immunosuppressants
like rituximab, cyclophosphamide, methylprednisolone,
prednisone and mycophenolate may not only reduce ret-
inal hemorrhagic vasculitis, but also result in remarkable
improvements in visual outcome.
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